Molecular Pathology and Genomics Core

分子病理学和基因组学核心

基本信息

批准号：
9791872
负责人：
JON C. ASTER
金额：
$ 29.08万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9791872
关键词：
Academic Medical Centers Address BCL1 Oncogene BCL2 gene Biological Markers Boston CLIA certified Cancer Center Cells Cities Classification Collection Color Complement Consensus DNA Dana-Farber Cancer Institute Data Data Analyses Development Diagnosis Diagnostic Equipment Evaluation Formalin Functional disorder Genes Genomics Genotype Hematologic Neoplasms Hematopathology Histology Histopathology Hospitals Human IL2RA gene Immune Immune response Immunofluorescence Immunologic In Situ Institution International Knowledge Link Lymphoma MCL1 gene MDM2 gene Medical Genetics Memorial Sloan-Kettering Cancer Center Modeling Mus Mutate Normal tissue morphology North Carolina Paraffin Embedding Pathologic Pathologist Pathology Periodicity Peripheral Primary Neoplasm Protocols documentation Research Research Personnel Resistance Resource Sharing Resources STAT5B gene Sampling Services Site Slide Stains System Systems Analysis T-Cell Lymphoma TP53 gene Testing Tissue Embedding Universities Woman actionable mutation analysis pipeline base cohort experience genomic data imaging platform innovation liquid crystal polymer molecular pathology mouse model neoplastic cell novel novel therapeutics performance site programs reagent standard response success targeted exome sequencing therapeutic target tumor microenvironment web interface web site working group

项目摘要

PROJECT SUMMARY Core C provides access to specialized professional and technical pathology services and genomic services that are essential to the success of the Program. It does so by carrying out 3 overarching aims that support all three P01 Projects: 1) provide pathology expertise needed for classification of primary human PTCLs and PDX and murine PTCL models; 2) perform standard and novel in situ tests for biomarkers relevant to understanding PTCL pathophysiology and its response and resistance to novel therapies; and 3) perform targeted exome sequencing of a large cohort of well-characterized human PTCLs. The Core delivers these services at two performance sites, one in Boston led by Jon Aster, which will deliver services supporting Aims 1 and 2, and the second in North Carolina led by Sandeep Dave, which will deliver services supporting Aims 1 and 3. Delivery of Aim 1 services relies on the Core's co-leader, Dr. Jon Aster, who is a practicing academic hematopathologist with >25 years of experience with human and murine hematopathology, and is supplemented by additional expertise in Project 1 (John Chan) and access to the Hematologic Malignancies Research Consortium, which includes >25 institutions and has accrued over 1800 cases of T cell lymphomas, a majority with paired normal tissue. Aim 2 services will be provided in Boston include standard histology and immunohistology services and innovative, multiparametric immunofluorescence staining platforms, the Perkin- Elmer Vectra platform and CyCIF is an iterative imaging platform that allows for evaluation of >50 different markers on single FFPE slides. Aim 3 services are delivered at the North Carolina performance site by performing targeted exome sequencing on 410 genes that are frequently mutated in lymphoma, initially using DNA prepared from a cohort of 1833 PTCLs and paired normal tissue controls.

项目摘要 Core C提供了专业专业和技术病理服务和基因组服务的访问权限这对于该计划的成功至关重要。它通过执行3个支持所有人的总体目标来做到这一点三个P01项目：1）提供对主要人类PTCL和PDX分类所需的病理专业知识和鼠PTCL模型； 2）对与理解有关的生物标志物进行标准和新颖的现场测试 PTCL的病理生理学及其对新疗法的反应和抵抗力； 3）执行针对性的外观大量特征良好的人类PTCL的测序。核心将这些服务提供两个性能站点，由乔恩·阿斯特（Jon Aster）领导的波士顿，该站点将提供支持AIM 1和2的服务，由桑德普·戴夫（Sandeep Dave）领导的北卡罗来纳州第二，该服务将提供支持目标1和3。 AIM 1服务依赖于核心的共同领导者乔恩·阿斯特（Jon Aster）博士，他是一名实践学术血管病理学家拥有> 25年的人类和鼠血液病理学经验，并且是补充项目1（约翰·陈）中的其他专业知识并获得血液恶性肿瘤研究联盟包括> 25个机构，并累积了1800多例T细胞淋巴瘤，大多数具有配对的正常组织。 AIM 2服务将在波士顿提供，包括标准组织学和免疫组织学服务和创新，多参数免疫荧光染色平台，Perkin- Elmer Vectra平台和Cycif是一个迭代成像平台，可以评估> 50个不同单个FFPE幻灯片上的标记。 AIM 3服务由对410个基因进行靶向外显子组测序，最初使用淋巴瘤突变的基因 DNA从1833年的PTCL和配对的正常组织对照组中制备。